VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q42774301 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241221010835.0
008 241221nneanz||abbn n and d
035 ‎‡a (WKP)Q42774301‏
024 ‎‡a 0000-0001-5441-9462‏ ‎‡2 orcid‏
024 ‎‡a 7201569309‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q42774301‏
100 0 ‎‡a Mu Moreno‏ ‎‡9 sl‏
400 0 ‎‡a Mu Moreno‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Mu Moreno‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
400 0 ‎‡a Mu Moreno‏ ‎‡c investigador/a‏ ‎‡9 es‏
400 0 ‎‡a Mu Moreno‏ ‎‡c investigador‏ ‎‡9 ast‏
670 ‎‡a Author's A novel CYBA variant, the -675A/T polymorphism, is associated with essential hypertension‏
670 ‎‡a Author's A synthetic peptide from transforming growth factor-β₁ type III receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats‏
670 ‎‡a Author's Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension‏
670 ‎‡a Author's Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahigh-density mapping study‏
670 ‎‡a Author's Association of phagocytic NADPH oxidase activity with hypertensive heart disease: a role for cardiotrophin-1?‏
670 ‎‡a Author's Blockade of TGF-β 1 signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats.‏
670 ‎‡a Author's Burden and challenges of heart failure in patients with chronic kidney disease. A call to action‏
670 ‎‡a Author's Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal.‏
670 ‎‡a Author's Circulating Long Noncoding RNA LIPCAR Predicts Heart Failure Outcomes in Patients Without Chronic Kidney Disease‏
670 ‎‡a Author's Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation‏
670 ‎‡a Author's CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation‏
670 ‎‡a Author's CYBA gene variants as biomarkers for coronary artery disease‏
670 ‎‡a Author's Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis.‏
670 ‎‡a Author's Functional effect of the p22phox -930A/G polymorphism on p22phox expression and NADPH oxidase activity in hypertension.‏
670 ‎‡a Author's Functional significance of single nucleotide polymorphisms within the 5′-flanking region of β2-adrenergic receptor gene‏
670 ‎‡a Author's Gene expression profiling in whole blood of patients with coronary artery disease‏
670 ‎‡a Author's Generation of eight adjacent mutations in a single step using a site-directed mutagenesis kit‏
670 ‎‡a Author's HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia.‏
670 ‎‡a Author's Impaired renal function impacts negatively on vascular stiffness in patients with coronary artery disease‏
670 ‎‡a Author's Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men.‏
670 ‎‡a Author's Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease.‏
670 ‎‡a Author's Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications.‏
670 ‎‡a Author's Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites.‏
670 ‎‡a Author's Myocardial Collagen Cross-Linking Is Associated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure‏
670 ‎‡a Author's Myocardial Remodeling in Hypertension‏
670 ‎‡a Author's NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease‏
670 ‎‡a Author's Oxidative stress and vascular remodelling.‏
670 ‎‡a Author's Oxidative stress, endothelial dysfunction and cerebrovascular disease‏
670 ‎‡a Author's Oxidative stress in arterial hypertension: role of NAD‏
670 ‎‡a Author's Oxidative stress in arterial hypertension: role of NAD(P)H oxidase.‏
670 ‎‡a Author's [Oxidative stress in hypertension: from the SNPs to the clinical phenotype]‏
670 ‎‡a Author's Phagocytic NADPH Oxidase-Dependent Superoxide Production Stimulates Matrix Metalloproteinase-9‏
670 ‎‡a Author's Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome‏
670 ‎‡a Author's Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome‏
670 ‎‡a Author's Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients.‏
670 ‎‡a Author's Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension‏
670 ‎‡a Author's Protective effect of the 1742‏
670 ‎‡a Author's Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension‏
670 ‎‡a Author's Reduced LDL-cholesterol levels in patients with coronary artery disease are paralleled by improved endothelial function: An observational study in patients from 2003 and 2007‏
670 ‎‡a Author's [Superoxide anion in the physiopathology of vascular diseases]‏
670 ‎‡a Author's The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes‏
670 ‎‡a Author's The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension.‏
670 ‎‡a Author's The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension‏
670 ‎‡a Author's The Hypertensive Myocardium: From Microscopic Lesions to Clinical Complications and Outcomes‏
670 ‎‡a Author's The renal immune-inflammatory component of arterial hypertension: Emerging therapeutic strategies‏
909 ‎‡a (scopus) 7201569309‏ ‎‡9 1‏
909 ‎‡a (orcid) 0000000154419462‏ ‎‡9 1‏
919 ‎‡a cybagenevariantsasbiomarkersforcoronaryarterydisease‏ ‎‡A CYBA gene variants as biomarkers for coronary artery disease‏ ‎‡9 1‏
919 ‎‡a combinationofcirculatingtype1collagenrelatedbiomarkersisassociatedwithatrialfibrillation‏ ‎‡A Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation‏ ‎‡9 1‏
919 ‎‡a preliminarycharacterisationofthepromoterofthehumanp22phoxgeneidentificationofanewpolymorphismassociatedwithhypertension‏ ‎‡A Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension‏ ‎‡9 1‏
919 ‎‡a circulatinglongnoncodingrnalipcarpredictsheartfailureoutcomesinpatientswithoutchronickidneydisease‏ ‎‡A Circulating Long Noncoding RNA LIPCAR Predicts Heart Failure Outcomes in Patients Without Chronic Kidney Disease‏ ‎‡9 1‏
919 ‎‡a circulatingbiomarkersofmyocardialfibrosistheneedforareappraisal‏ ‎‡A Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal.‏ ‎‡9 1‏
919 ‎‡a protectiveeffectofthe‏ ‎‡A Protective effect of the 1742‏ ‎‡9 1‏
919 ‎‡a protectiveeffectofthe1742100gpolymorphismofhumancardiotrophin1againstleftventricularhypertrophyinessentialhypertension‏ ‎‡A Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension‏ ‎‡9 1‏
919 ‎‡a burdenandchallengesofheartfailureinpatientswithchronickidneydiseaseacalltoaction‏ ‎‡A Burden and challenges of heart failure in patients with chronic kidney disease. A call to action‏ ‎‡9 1‏
919 ‎‡a blockadeoftgfβ1signallinginhibitscardiacnadphoxidaseoveractivityinhypertensiverats‏ ‎‡A Blockade of TGF-β 1 signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats.‏ ‎‡9 1‏
919 ‎‡a associationofphagocyticnadphoxidaseactivitywithhypertensiveheartdiseasearoleforcardiotrophin1‏ ‎‡A Association of phagocytic NADPH oxidase activity with hypertensive heart disease: a role for cardiotrophin-1?‏ ‎‡9 1‏
919 ‎‡a reducedldlcholesterollevelsinpatientswithcoronaryarterydiseaseareparalleledbyimprovedendothelialfunctionanobservationalstudyinpatientsfrom2003and‏ ‎‡A Reduced LDL-cholesterol levels in patients with coronary artery disease are paralleled by improved endothelial function: An observational study in patients from 2003 and 2007‏ ‎‡9 1‏
919 ‎‡a associationofleftatriumvoltageamplitudeanddistributionwiththeriskofatrialfibrillationrecurrenceandevolutionafterpulmonaryveinisolationanultrahighdensitymappingstudy‏ ‎‡A Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahigh-density mapping study‏ ‎‡9 1‏
919 ‎‡a superoxideanioninthephysiopathologyofvasculardiseases‏ ‎‡A [Superoxide anion in the physiopathology of vascular diseases]‏ ‎‡9 1‏
919 ‎‡a associationofincreasedphagocyticnadphoxidasedependentsuperoxideproductionwithdiminishednitricoxidegenerationinessentialhypertension‏ ‎‡A Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension‏ ‎‡9 1‏
919 ‎‡a syntheticpeptidefromtransforminggrowthfactorβ1type3receptorinhibitsnadphoxidaseandpreventsoxidativestressinthekidneyofspontaneouslyhypertensiverats‏ ‎‡A A synthetic peptide from transforming growth factor-β₁ type III receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats‏ ‎‡9 1‏
919 ‎‡a novelcybavariantthe675atpolymorphismisassociatedwithessentialhypertension‏ ‎‡A A novel CYBA variant, the -675A/T polymorphism, is associated with essential hypertension‏ ‎‡9 1‏
919 ‎‡a a640gcybapolymorphismassociateswithsubclinicalatherosclerosisindiabetes‏ ‎‡A The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes‏ ‎‡9 1‏
919 ‎‡a angiotensinconvertingenzymeinsertiondeletionpolymorphismisassociatedwithphagocyticnadphoxidasedependentsuperoxidegenerationpotentialimplicationinhypertension‏ ‎‡A The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension.‏ ‎‡9 1‏
919 ‎‡a c242tcybapolymorphismofnadphoxidaseisassociatedwithessentialhypertension‏ ‎‡A The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension‏ ‎‡9 1‏
919 ‎‡a hypertensivemyocardiumfrommicroscopiclesionstoclinicalcomplicationsandoutcomes‏ ‎‡A The Hypertensive Myocardium: From Microscopic Lesions to Clinical Complications and Outcomes‏ ‎‡9 1‏
919 ‎‡a renalimmuneinflammatorycomponentofarterialhypertensionemergingtherapeuticstrategies‏ ‎‡A The renal immune-inflammatory component of arterial hypertension: Emerging therapeutic strategies‏ ‎‡9 1‏
919 ‎‡a ct1cardiotrophin1gal3galectin3axisincardiacfibrosisandinflammation‏ ‎‡A CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation‏ ‎‡9 1‏
919 ‎‡a increasedphagocyticnicotinamideadeninedinucleotidephosphateoxidasedependentsuperoxideproductioninpatientswithearlychronickidneydisease‏ ‎‡A Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease.‏ ‎‡9 1‏
919 ‎‡a increasedphagocyticnadphoxidaseactivityassociateswithcoronaryarterycalcificationinasymptomaticmen‏ ‎‡A Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men.‏ ‎‡9 1‏
919 ‎‡a isleptininvolvedinphagocyticnadphoxidaseoveractivityinobesitypotentialclinicalimplications‏ ‎‡A Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications.‏ ‎‡9 1‏
919 ‎‡a impairedrenalfunctionimpactsnegativelyonvascularstiffnessinpatientswithcoronaryarterydisease‏ ‎‡A Impaired renal function impacts negatively on vascular stiffness in patients with coronary artery disease‏ ‎‡9 1‏
919 ‎‡a mechanismsunderlyingthecardiacantifibroticeffectsoflosartanmetabolites‏ ‎‡A Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites.‏ ‎‡9 1‏
919 ‎‡a myocardialcollagencrosslinkingisassociatedwithheartfailurehospitalizationinpatientswithhypertensiveheartfailure‏ ‎‡A Myocardial Collagen Cross-Linking Is Associated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure‏ ‎‡9 1‏
919 ‎‡a hif1mediatedupregulationofcardiotrophin1isinvolvedinthesurvivalresponseofcardiomyocytestohypoxia‏ ‎‡A HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia.‏ ‎‡9 1‏
919 ‎‡a myocardialremodelinginhypertension‏ ‎‡A Myocardial Remodeling in Hypertension‏ ‎‡9 1‏
919 ‎‡a generationof8adjacentmutationsinasinglestepusingasitedirectedmutagenesiskit‏ ‎‡A Generation of eight adjacent mutations in a single step using a site-directed mutagenesis kit‏ ‎‡9 1‏
919 ‎‡a geneexpressionprofilinginwholebloodofpatientswithcoronaryarterydisease‏ ‎‡A Gene expression profiling in whole blood of patients with coronary artery disease‏ ‎‡9 1‏
919 ‎‡a functionalsignificanceofsinglenucleotidepolymorphismswithinthe5flankingregionofβ2adrenergicreceptorgene‏ ‎‡A Functional significance of single nucleotide polymorphisms within the 5′-flanking region of β2-adrenergic receptor gene‏ ‎‡9 1‏
919 ‎‡a functionaleffectofthep22phox930agpolymorphismonp22phoxexpressionandnadphoxidaseactivityinhypertension‏ ‎‡A Functional effect of the p22phox -930A/G polymorphism on p22phox expression and NADPH oxidase activity in hypertension.‏ ‎‡9 1‏
919 ‎‡a nadphoxidasedependentsuperoxideproductionisassociatedwithcarotidintimamediathicknessinsubjectsfreeofclinicalatheroscleroticdisease‏ ‎‡A NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease‏ ‎‡9 1‏
919 ‎‡a oxidativestressandvascularremodelling‏ ‎‡A Oxidative stress and vascular remodelling.‏ ‎‡9 1‏
919 ‎‡a oxidativestressendothelialdysfunctionandcerebrovasculardisease‏ ‎‡A Oxidative stress, endothelial dysfunction and cerebrovascular disease‏ ‎‡9 1‏
919 ‎‡a oxidativestressinarterialhypertensionroleofnad‏ ‎‡A Oxidative stress in arterial hypertension: role of NAD‏ ‎‡9 1‏
919 ‎‡a oxidativestressinarterialhypertensionroleofnadphoxidase‏ ‎‡A Oxidative stress in arterial hypertension: role of NAD(P)H oxidase.‏ ‎‡9 1‏
919 ‎‡a oxidativestressinhypertensionfromthesnpstotheclinicalphenotype‏ ‎‡A [Oxidative stress in hypertension: from the SNPs to the clinical phenotype]‏ ‎‡9 1‏
919 ‎‡a phagocyticnadphoxidasedependentsuperoxideproductionstimulatesmatrixmetalloproteinase9‏ ‎‡A Phagocytic NADPH Oxidase-Dependent Superoxide Production Stimulates Matrix Metalloproteinase-9‏ ‎‡9 1‏
919 ‎‡a phagocyticnadphoxidaseoveractivityunderliesoxidativestressinmetabolicsyndrome‏ ‎‡A Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome‏ ‎‡9 1‏
919 ‎‡a phenotypingofmyocardialfibrosisinhypertensivepatientswithheartfailureinfluenceonclinicaloutcome‏ ‎‡A Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome‏ ‎‡9 1‏
919 ‎‡a potentialroleofmicrorna10bdownregulationincardiomyocyteapoptosisinaorticstenosispatients‏ ‎‡A Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients.‏ ‎‡9 1‏
919 ‎‡a decreasednox4levelsinthemyocardiumofpatientswithaorticvalvestenosis‏ ‎‡A Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis.‏ ‎‡9 1‏
943 ‎‡a 174x‏ ‎‡A 1742‏ ‎‡9 1‏
943 ‎‡a 200x‏ ‎‡A 2007‏ ‎‡9 1‏
996 ‎‡2 PLWABN|9810650886905606‏
996 ‎‡2 ISNI|000000005922291X‏
996 ‎‡2 SUDOC|165315598‏
996 ‎‡2 BNC|981058513079706706‏
996 ‎‡2 ISNI|000000011779153X‏
996 ‎‡2 ISNI|0000000118529285‏
996 ‎‡2 BNF|15372488‏
996 ‎‡2 BNE|XX1066389‏
996 ‎‡2 DNB|1024334368‏
996 ‎‡2 BNCHL|10000000000000000016714‏
996 ‎‡2 BNE|XX1499291‏
996 ‎‡2 ISNI|0000000116443496‏
996 ‎‡2 LC|no2017087625‏
996 ‎‡2 NTA|29426132X‏
996 ‎‡2 ISNI|0000000081249422‏
996 ‎‡2 ISNI|0000000070234372‏
996 ‎‡2 ISNI|0000000059433207‏
996 ‎‡2 BNE|XX4660604‏
996 ‎‡2 DNB|171926110‏
996 ‎‡2 ISNI|000000005938023X‏
996 ‎‡2 ISNI|0000000119871963‏
996 ‎‡2 BNC|981058610700206706‏
996 ‎‡2 BNE|XX1107581‏
996 ‎‡2 DNB|1333263821‏
996 ‎‡2 ISNI|000000011208975X‏
996 ‎‡2 NUKAT|n 2005095883‏
996 ‎‡2 ISNI|0000000059236174‏
996 ‎‡2 ISNI|0000000073595827‏
996 ‎‡2 NSK|000486790‏
996 ‎‡2 ISNI|0000000060845700‏
996 ‎‡2 BNE|XX913393‏
996 ‎‡2 BIBSYS|90253285‏
996 ‎‡2 PTBNP|216741‏
996 ‎‡2 SUDOC|260580848‏
996 ‎‡2 BNE|XX930847‏
996 ‎‡2 BNC|981058518726706706‏
996 ‎‡2 ISNI|0000000359713542‏
996 ‎‡2 BNC|981061104213906706‏
996 ‎‡2 SUDOC|273184598‏
996 ‎‡2 BNE|XX980633‏
996 ‎‡2 BNE|XX5502583‏
996 ‎‡2 DNB|1085662098‏
996 ‎‡2 BLBNB|000471861‏
996 ‎‡2 BNC|981058509343606706‏
996 ‎‡2 BNC|981058513987606706‏
996 ‎‡2 BNE|XX1333321‏
996 ‎‡2 ISNI|0000000068604688‏
996 ‎‡2 NUKAT|n 2013077354‏
996 ‎‡2 ISNI|0000000060342716‏
996 ‎‡2 BNE|XX860705‏
996 ‎‡2 ISNI|0000000119860359‏
996 ‎‡2 LC|n 78005139‏
996 ‎‡2 BNC|981058608583006706‏
996 ‎‡2 ISNI|0000000418315027‏
996 ‎‡2 ISNI|0000000117084739‏
996 ‎‡2 BNE|XX1669613‏
996 ‎‡2 ISNI|0000000060058504‏
996 ‎‡2 BNE|XX835478‏
996 ‎‡2 LC|nr2006027901‏
996 ‎‡2 BNE|XX1288578‏
996 ‎‡2 ISNI|0000000060286304‏
996 ‎‡2 BNE|XX1674099‏
996 ‎‡2 ISNI|0000000059335682‏
996 ‎‡2 BNE|XX1103157‏
996 ‎‡2 DNB|1047945339‏
996 ‎‡2 ISNI|0000000060448860‏
996 ‎‡2 BNE|XX1298487‏
996 ‎‡2 J9U|987007318552505171‏
996 ‎‡2 BNC|981058529581006706‏
996 ‎‡2 PLWABN|9810659382105606‏
996 ‎‡2 SUDOC|142679232‏
996 ‎‡2 PTBNP|88068‏
996 ‎‡2 BIBSYS|90312766‏
996 ‎‡2 BNE|XX1531022‏
996 ‎‡2 CAOONL|ncf10608241‏
996 ‎‡2 SIMACOB|331942755‏
996 ‎‡2 BNE|XX4829502‏
996 ‎‡2 ISNI|0000000002107689‏
996 ‎‡2 ISNI|0000000116152605‏
996 ‎‡2 BNCHL|10000000000000000194320‏
996 ‎‡2 SUDOC|059544708‏
996 ‎‡2 BNE|XX855744‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏